A Randomized Trial of Hydroxychloroquine as Postexposure Prophylaxis for Covid-19.
David R BoulwareMatthew F PullenAnanta S BangdiwalaKatelyn A PastickSarah M LofgrenElizabeth C OkaforCaleb P SkipperAlanna A NasceneMelanie R NicolMahsa AbassiNicole W EngenMatthew P ChengDerek LaBarSylvain A LotherLauren J MacKenzieGlen DrobotNicole MartenRyan ZarychanskiLauren E KellyIlan S SchwartzEmily G McDonaldRadha RajasinghamTodd C LeeKathy H HullsiekPublished in: The New England journal of medicine (2020)
After high-risk or moderate-risk exposure to Covid-19, hydroxychloroquine did not prevent illness compatible with Covid-19 or confirmed infection when used as postexposure prophylaxis within 4 days after exposure. (Funded by David Baszucki and Jan Ellison Baszucki and others; ClinicalTrials.gov number, NCT04308668.).